Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients

Nivolumab, a monoclonal antibody targeting PD-1, is currently approved for metastatic non-small cell lung cancer (mNSCLC) treatment after failure of first-line chemotherapy. However, only a quarter of patients benefit from this therapy with objective clinical response. In this context, there is an u...

Descripción completa

Detalles Bibliográficos
Autores principales: Limagne, Emeric, Richard, Corentin, Thibaudin, Marion, Fumet, Jean-David, Truntzer, Caroline, Lagrange, Aurélie, Favier, Laure, Coudert, Bruno, Ghiringhelli, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422400/
https://www.ncbi.nlm.nih.gov/pubmed/30906658
http://dx.doi.org/10.1080/2162402X.2018.1564505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422400/
https://www.ncbi.nlm.nih.gov/pubmed/30906658
http://dx.doi.org/10.1080/2162402X.2018.1564505

Ejemplares similares